Taxotere Could Get Boost From NICE Prostate Cancer Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K.’s National Institute for Health & Clinical Excellence recommends coverage of Sanofi-Aventis’ docetaxal for hormone-refractory metastatic prostate cancer.